MediPharm Labs Corp.
LABS.TO
TSX
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Net Income | -2.03M | -1.89M | -2.68M | -2.18M | -3.23M |
Total Depreciation and Amortization | 379.80K | 534.20K | 586.00K | 527.00K | 460.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 525.00K | 600.00K | 568.90K | -1.07M | -603.90K |
Change in Net Operating Assets | 643.70K | -420.20K | 391.60K | 3.80M | 960.30K |
Cash from Operations | -485.40K | -1.17M | -1.13M | 1.08M | -2.41M |
Capital Expenditure | -24.20K | -40.90K | -15.60K | -87.50K | -193.80K |
Sale of Property, Plant, and Equipment | -- | 15.30K | 405.00K | 130.80K | 1.42M |
Cash Acquisitions | -- | -- | -- | 0.00 | -- |
Divestitures | -- | -- | -- | 3.12M | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -24.20K | -25.60K | 389.40K | 3.17M | 1.22M |
Total Debt Issued | 50.00K | 749.00K | -- | 0.00 | -- |
Total Debt Repaid | -2.29M | -153.00K | -269.00K | -391.00K | -388.00K |
Issuance of Common Stock | -- | -- | -- | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 20.00K | 89.00K | 203.00K | 150.00K | 89.00K |
Cash from Financing | -1.63M | 500.60K | -49.00K | -177.10K | -222.90K |
Foreign Exchange rate Adjustments | 13.20K | 15.30K | 8.90K | -374.90K | 71.60K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -2.13M | -683.30K | -782.50K | 3.70M | -1.34M |